Related references
Note: Only part of the references are listed.Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All
Sumithra J. Mandrekar et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
The Use of Genomics in Clinical Trial Design
Richard Simon
CLINICAL CANCER RESEARCH (2008)
Validation of Analytic Methods for Biomarkers Used in Drug Development
Cindy H. Chau et al.
CLINICAL CANCER RESEARCH (2008)
Randomized phase III clinical trial designs for targeted agents
Antje Hoering et al.
CLINICAL CANCER RESEARCH (2008)
Development of the 21-gene assay and its application in clinical practice and clinical trials
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
Alessandra Gennari et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
HER2 and response to paclitaxel in node-positive breast cancer
Daniel F. Hayes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A method for testing a prespecified subgroup in clinical trials
Yang Song et al.
STATISTICS IN MEDICINE (2007)
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
Wenyu Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
Sue-Jane Wang et al.
PHARMACEUTICAL STATISTICS (2007)
Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting
Alain Dupuy et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen
Soonmyung Paik
ONCOLOGIST (2007)
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
Jan Bogaerts et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Increased bioavailability of intravenous versus oral Cl-1033, a pan erbB tyrosine kinase inhibitor: Results of a phase I pharmacokinetic study
George R. Simon et al.
CLINICAL CANCER RESEARCH (2006)
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer
N. Lynn Henry et al.
ONCOLOGIST (2006)
Use of genomic signatures in therapeutics development in oncology and other diseases
R. Simon et al.
PHARMACOGENOMICS JOURNAL (2006)
Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
B Freidlin et al.
CLINICAL CANCER RESEARCH (2005)
Prediction error estimation: a comparison of resampling methods
AM Molinaro et al.
BIOINFORMATICS (2005)
On the efficiency of targeted clinical trials
A Maitournam et al.
STATISTICS IN MEDICINE (2005)
Clinical trial designs for prospective validation of biomarkers
SJ Mandrekar et al.
AMERICAN JOURNAL OF PHARMACOGENOMICS (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Evaluating the efficiency of targeted designs for randomized clinical trials
R Simon et al.
CLINICAL CANCER RESEARCH (2004)
Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker
MS Pepe et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)
Time-dependent ROC curves for censored survival data and a diagnostic marker
PJ Heagerty et al.
BIOMETRICS (2000)
Share Paper
